Form 4: TG Therapeutics Director Charney Receives Stock Grant

Laurence N. Charney, a director at TG Therapeutics, acquired 22,250 shares of common stock through a grant on June 19, 2024.

Summary

• On June 19, 2024, Laurence N. Charney, a director of TG Therapeutics, acquired 22,250 shares of common stock.
• The acquisition was a grant of restricted shares.
• These shares will vest on June 14, 2025.
• Following the transaction, Charney beneficially owns 237,479 shares of TG Therapeutics common stock, including restricted shares vesting over various time periods.

Sentiment

Score: 6

Explanation: The document reflects a standard transaction (stock grant) and doesn't contain overtly positive or negative information. It's a neutral event from an investment perspective.

Positives

• The grant of restricted shares to a director aligns their interests with the long-term performance of the company.

Industry Context

Stock grants to directors are a common practice in the pharmaceutical industry to incentivize and align their interests with the company's success.

Stakeholder Impact

• The stock grant could have a minor positive impact on shareholder sentiment by aligning director interests with company performance.

Key Dates